FarmavitaR+

1. Advances in Imaging Biomarkers
(Reports/Market Report)

Innovative technologies, applications in R&D and clinical practice, and informatics and regulatory requirements This report discusses advances in key technologies, the use of imaging biomarkers ...

2. Adaptive Clinical Trials
(Events/Events)

Design Optimization and Implementation for Adaptive Clinical Trials October 7-8, 2010 Jersey City, NJ, USA In attending this premier marcus evans conference you will gain a better understanding ...

3. Clinical Trials 2010
(Events/Events)

Clinical Trials 2010 29th-30th September Frankfurt, Germany North West Business Group is proud to present the conference “Clinical Triasl 2010” in Frankfurt Germany. The Clinical Trials 2010 is ...

4. How to run the right clinical trials?
(Events/Events)

6th Annual Future of Clinical Trials 26th&27th October 2010, Vienna Leading Pharmaceutical players understand, how to complete trials with greater levels of cost-efficiency, timelines and success.  ...

5. Achieving preferential patient-access through innovative agreements with payers
(Events/Events)

... difficult choices need to be made by payers and HTAs about which products receive funding from increasingly restricted healthcare budgets, especially with often insufficient clinical and real-life evidence ...

6. Evolution Summit 2010
(Business News/Press Release)

  Overcoming International Obstacles in Clinical Trial Operations   Bernard Coulie, a speaker at the marcus evans Evolution Summit 2010 addresses the international barriers facing Chief Medical ...

7. Pricing and Reimbursement Conference Review
(Pricing and Reimbursment/Pricing and Reimbursment)

... of our product upon its release? Is it post-authorization data collection an objective way to confirm the value of your product which was already confirmed by controlled clinical trials? How can we ...

8. Patern Ltd.
(Partners/Regulatory Affairs)

... affairs, registration, renewal and variation of original and generic products, in-bulk, medical devices, nutritional supplements and healthcare cosmetic. · Clinical and pre-clinical trials in Ukraine. ...

9. Patern Ltd.
(Partners/Regulatory Affairs)

... ISO 9001:2008 standards. Regulatory affairs, registration, renewal and variation of original and generic products, in-bulk, medical devices, nutritional supplements and healthcare cosmetic; Clinical ...

10. Emerging Clinical Trial Locations
(Clinical Trilas/Europe not-EU)

Emerging Clinical Trial Locations: Market dynamics and the changing healthcare and regulatory environment This report provides a comprehensive examination of the clinical trial landscape in emerging ...

11. Key Trends In Drug-diagnostic Co-development
(Reports/Market Report)

... II clinical trial completion. Third-party studies will be a significant driver in gaining acceptance for the use of pharmacogenomic information to optimize drug usage. Work currently being done by US ...

12. New Approaches to Pharma R&D
(Reports/Market Report)

... in an effort to increase efficiency and output. GlaxoSmithKline, Pfizer and AstraZeneca have the largest preclinical and clinical drug pipelines, each with approximately 200 candidates in development ...

13. Clinical Trial in India
(Clinical Trilas/Asia)

CLINICAL TRIAL IN INDIA-AN OVERVIEW Global Pharmaceutical companies based in developed countries are increasingly turning to developing countries and emerging economies around the world for conducting ...

14. Standardization of Herbal Drugs
(Professional Articles/Life Science Article)

... must be approved (Bauer et al., 1994).Also, their composition needs to be well documented in order to obtain reproducible results in pharmacological, toxicological and clinical studies (Bauer and Tittel, ...

15. Drug repositioning
(Regulatory Affairs/Other issues)

... one in 5,000 chance of approval, with just three out of 10 drugs that actually reach the market providing a return on the R&D investment. It is also estimated that 90% of all drugs entering clinical ...

16. Early Stage Drug Safety Strategies and Risk Management
(Reports/Market Report)

Maximizing opportunities towards achieving clinical success For the last few years the biggest pharma companies have started to bring new technologies for drug safety prediction into the discovery ...

17. NMA of Romania News Flash
(Regulatory Affairs/European Union)

... on the EMEA website, under Inspections – Good Clinical Practices (http://www.emea.europa.eu/Inspections/GCPproc.html) of the reflection paper on advice to Applicants/Sponsors/CROs of Bioequivalence Studies. ...

18. Valuing Pharmaceutical Innovation
(Reports/Market Report)

Valuing Pharmaceutical Innovation: Pricing and reimbursement for innovative therapies Pricing and reimbursement strategies for innovative new drugs require significant evidence of beneficial clinical ...

19. eCTD
(eSubmissions/eSubmissions)

... sharpen up and standardise on the formats used to manage clinical and safety data. Although these changes create another administrative burden for companies, however, they also provide a valuable catalyst ...

20. New tariffs for MA in Romania
(Regulatory Affairs/European Union)

... via national procedure/ MRP and DCP, for variations, for renewals of MA, for clinical trials etc.). So, the new tariffs for obtaining MA through European procedures (MRP and DCP) are as follows:  ...